![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 41, 29005-29010, October 8, 1999
From the Departments of We have cloned a transporter protein from rabbit
small intestine, which, when coexpressed with the 4F2 heavy chain
(4F2hc) in mammalian cells, induces a b0,+-like amino
acid transport activity. This protein (4F2-lc6 for the sixth member of
the 4F2 light chain family) consists of 487 amino acids and has 12 putative transmembrane domains. At the level of amino acid sequence,
4F2-lc6 shows significant homology (44% identity) to the other five
known members of the 4F2 light chain family, namely LAT1 (4F2-lc1),
y+LAT1 (4F2-lc2), y+LAT2 (4F2-lc3), xCT
(4F2-lc4), and LAT2 (4F2-lc5). The 4F2hc/4F2-lc6 complex-mediated
transport process is Na+-independent and exhibits high
affinity for neutral and cationic amino acids and cystine. These
characteristics are similar to those of the b0,+-like amino
acid transport activity previously shown to be associated with rBAT
(protein related to b0,+ amino acid transport system).
However, the newly cloned 4F2-lc6 does not interact with rBAT. This is
the first report of the existence of a b0,+-like amino acid
transport process that is independent of rBAT. 4F2-lc6 is expressed
predominantly in the small intestine and kidney. Based on the
characteristics of the transport process mediated by the 4F2hc/4F2-lc6
complex and the expression pattern of 4F2-lc6 in mammalian tissues, we
suggest that 4F2-lc6 is a new candidate gene for cystinuria.
Cystinuria is a genetic disorder in the transport of neutral and
cationic amino acids and cystine in the intestine and kidney (1-5).
Three groups of investigators have independently cloned a protein
associated with an amino acid transport function with specificity
toward neutral and cationic amino acids and cystine (6-8). This
protein, referred to as NBAT, D2, or
rBAT1 (the term rBAT is used
in this paper to refer to this protein), is expressed in the intestinal
and renal tubular cells (9). When expressed heterologously in
Xenopus laevis oocytes, rBAT induces an amino acid transport
activity similar to system b0,+ (7, 8), originally
described in mouse blastocysts as a Na+-independent high
affinity system for neutral and cationic amino acids (10). Subsequent
studies have revealed that the gene coding for rBAT is defective in
some patients with cystinuria (3, 5, 11, 12). Interestingly rBAT is not
very hydrophobic, a characteristic rather unusual for a transport
protein. The prevailing hypothesis is that rBAT does not constitute the
transport system per se, but may be an essential subunit
associated with the transport system (12). The molecular identity of
the other subunits(s) that interact(s) with rBAT to form the transport
system remains unknown. The fact that defects in the rBAT
gene account for some but not all cystinuria cases indicates that other
genes, hitherto unidentified, are also involved in this disease.
Biochemical evidence suggests that cystinuria is comprised of three
genetically distinct diseases (13). Mutational analyses have shown that
defects in the rBAT gene are exclusively associated with
type I cystinuria. However, there are cases of type I cystinuria with
no detectable defects in the rBAT gene, and the identity of
the gene responsible for these cases is not known. Similarly, the genes
associated with type II and type III cystinuria have also not yet been identified.
rBAT exhibits significant homology to 4F2hc, the heavy chain of the
cell surface antigen 4F2 (7, 8). Expression of 4F2hc in X. laevis oocytes also induces an amino acid transport activity that
is distinct from the activity induced by rBAT (14, 15). The
characteristics of 4F2hc-related transport activity resemble those of
y+L (16), a system which mediates
Na+-independent transport of cationic amino acids and
Na+-dependent transport of neutral amino acids
(17). Recent studies have shown that 4F2hc is a subunit common to at
least three different amino acid transport systems, namely L,
y+L, and xc Here we report the cloning of a protein from the rabbit small
intestine, which, when coexpressed with 4F2hc in mammalian cells, induces a Na+-independent amino acid transport activity
specific for neutral and cationic amino acids and cystine. Even though
this transport activity is similar to the activity associated with
rBAT, the newly cloned protein does not interact with rBAT. This
protein is the sixth member of the 4F2 light chain family to be
identified that interacts with the 4F2 heavy chain to constitute an
amino acid transport system. Accordingly, we have named this protein 4F2-lc6. The other five are 4F2-lc1 (LAT1), 4F2-lc2
(y+LAT1), 4F2-lc3 (y+LAT2), 4F2-lc4 (xCT), and
4F2-lc5 (LAT2). Based on the functional characteristics of the
transport system induced by the 4F2hc/4F2-lc6 complex, we hypothesize
that 4F2-lc6 may represent a new candidate gene for
cystinuria. These studies provide the first evidence for the existence
of a b0,+-like amino acid transport activity independent of
rBAT.
Materials--
Radiolabeled amino acids and nucleotides were
purchased from NEN Life Science Products, American Radiolabeled
Chemicals, or Amersham Pharmacia Biotech. Unlabeled amino acids were
from Sigma. Nitropure nitrocellulose transfer membranes used in the
library screening were purchased from Micron Separations, Inc.
(Westboro, MA). The Ready-to-go oligolabeling kit was purchased from
Amersham Pharmacia Biotech. Lipofectin, TRIzol reagent, and
oligo(dT)-cellulose were purchased from Life Technologies, Inc.
Restriction enzymes were from New England Biolabs. The human retinal
pigment epithelial (HRPE) cell line 165, used in expression studies,
has been described earlier from our laboratory (28, 29). The human rBAT
cDNA and rat 4F2hc cDNA were kindly provided by Matthias A. Hediger (Department of Medicine, Harvard University, Boston, MA). The human 4F2hc cDNA was isolated by screening a JAR human placental trophoblast cell line cDNA library (30) using the rat 4F2hc cDNA as a probe.
cDNA Library Screening and DNA Sequencing--
The cDNA
probe used for the screening was a 1.7-kilobase pair fragment of human
LAT1 cDNA (20) obtained by digestion of the full-length cDNA
with KpnI/PvuII. The probe was labeled with [ Functional Expression of the cDNA in HRPE Cells--
The
vaccinia virus expression system was used to functionally characterize
the cloned cDNA as described previously (20, 30-32). 4F2-lc6, rat
and human 4F2hc, and human rBAT were all cloned into pSPORT such that
the sense transcription is under the control of T7 promoter. The
cDNAs were transfected into HRPE cells grown in 24-well tissue
culture plates using Lipofectin, and the functional expression of the
cDNA was analyzed 12 h later by measuring radiolabeled amino
acid uptake. One microgram of the plasmid carrying the specific cDNA (4F2-lc6, 4F21hc, or rBAT) was used per well. Sister wells transfected identically with vector alone served as control. The transport buffer was composed of 25 mM Hepes/Tris (pH 7.5),
supplemented with 140 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 0.8 mM MgSO4,
and 5 mM glucose. When the effect of Na+ on
amino acid uptake was studied, the NaCl in the buffer was replaced with
N-methyl-D-glucamine chloride. The incubation
time for the transport measurements was 15 min in most cases, following which the uptake medium containing the radioactive substrate was aspirated off and the cells were washed with 2 × 2 ml of ice-cold transport buffer. The cells were then solubilized in 0.5% SDS in 0.2 N NaOH, transferred to vials, and radioactivity associated with the cells quantitated by liquid scintillation spectrometry. The
experiments were repeated two to three times with independent transfections, each done in duplicate or triplicate. Data are presented
as means ± S.E. of these replicate measurements.
Functional Expression in X. laevis Oocytes--
Isolation of
mature oocytes from X. laevis, cRNA synthesis, and
microinjection of cRNA into oocytes have been described previously (16,
30, 31). Uptake of radiolabeled amino acids into oocytes was measured
for 60 min in the uptake buffer, composed of 100 mM NaCl, 2 mM KCl, 1 mM MgCl2, and 1 mM CaCl2, buffered with 3 mM
Hepes/Tris, pH 7.5.
Northern Blot Analysis--
Poly(A)+ RNA, isolated
from different rabbit tissues (small intestine, kidney, heart, lung,
liver, and skeletal muscle), was used for Northern blot analysis. The
membrane filter containing the size-fractionated RNA (5 µg/lane) was
probed sequentially, first with the 4F2-lc6 cDNA and then,
following stripping, with cyclophilin cDNA.
RT-PCR--
Poly(A)+ RNA samples prepared from
rabbit tissues were used for RT-PCR. The upstream primer was
5'-CCGCCTACCTCTTCTCCT-3', and the downstream primer was
5'-CGCTGGGTTAGTGATGAC-3'. These primers correspond to nucleotide
positions 405-422 and 1367-1384 of the rabbit intestinal 4F2-lc6
cDNA. The RT-PCR products were subcloned into pGEM-T vector and the
inserts were analyzed for restriction pattern and nucleotide sequence.
Structural Features of 4F2-lc6--
The rabbit intestinal 4F2-lc6
cDNA is 1858 bp long, with an open reading frame consisting of 1464 bp (including the termination codon). The cDNA codes for a protein
of 487 amino acids (Fig. 1A).
The open reading frame is flanked by a 82-bp 5'-noncoding sequence and
a 312-bp 3'-noncoding sequence (GenBank accession no. AF155119). The
predicted molecular mass of the protein is 53.6 kDa. Hydrophobicity
analysis of the amino acid sequence suggests the presence of 12 putative transmembrane domains. When modeled similar to most of the
transporter proteins with both the N terminus and C terminus facing the
cytoplasmic surface of the lipid bilayer, there is one potential site
for N-linked glycosylation (Asn-271) in the extracellular
loop between transmembrane domains 7 and 8 (Fig. 1B). The
protein contains three potential sites for protein kinase
C-dependent phosphorylation (Ser-169, Ser-345, and Thr-399)
and one potential site for cAMP- and cGMP-dependent protein
kinase phosphorylation (Thr-350) in putative intracellular domains. At
the level of amino acid sequence, the rabbit 4F2-lc6 exhibits
significant homology to the other known members of the 4F2 light chain
family, namely 4F2-lc1 (LAT1), 4F2-lc2 (y+LAT1), 4F2-1c3
(y+LAT2), 4F2-lc4 (xCT), and 4F2-lc5 (LAT2). The amino acid
sequence identity is 43-44%, and similarity is 63-65%.
Functional Characteristics of 4F2-lc6--
The structural
similarity of 4F2-lc6 to the known light chains associated with 4F2hc
suggested that 4F2-lc6 may be a protein which works with 4F2hc to form
a new heterodimeric amino acid transport system. To establish the
functional identity of 4F2-lc6, we expressed 4F2-lc6 cDNA either
alone or together with human 4F2hc cDNA in HRPE cells using the
vaccinia virus expression system and studied the transport of a neutral
amino acid (alanine) in the presence or absence of Na+
(Fig. 2A and B). In
the presence of Na+, neither 4F2-lc6 nor 4F2hc mediated
alanine transport. The transport activity in either case was not
different from the transport activity in control cells transfected with
vector alone. Similarly, the transport activity remained essentially
the same even when 4F2-lc6 was coexpressed with 4F2hc. In contrast to
the results obtained in the presence of Na+, an increase in
alanine transport was seen in cells coexpressing the two proteins when
the transport was measured in the absence of Na+.
Expression of either 4F2-lc6 or 4F2hc alone did not show any increase
in alanine transport under similar conditions. These data demonstrate
that the 4F2hc/4F2-lc6 heterodimeric complex mediates
Na+-independent transport of the neutral amino acid
alanine. Na+-independent alanine transport activity was
also demonstrable with the heterodimeric complex consisting of 4F2-lc6
and rat 4F2hc (data not shown). It is of some interest that the
heterodimer-mediated alanine transport could not be detected when
measured in the presence of Na+. A
Na+-independent transport process is expected to be
detectable both in the presence and absence of Na+. It is
possible that the high endogenous alanine transport activity seen in
the presence of Na+ masks the transport activity associated
with the 4F2hc/4F2-lc6 complex in this experimental system.
We then tested whether 4F2-lc6 is capable of working with rBAT instead
of 4F2hc to induce the Na+-independent alanine transport
activity (Fig. 2C). Human rBAT cDNA and 4F2-lc6 cDNA
were expressed either independently or together in HRPE cells and
alanine transport was measured in the absence of Na+. These
were the same experimental conditions in which the alanine transport
activity of the 4F2hc/4F2-lc6 complex was demonstrable. The data given
in Fig. 2C show that there was no alanine transport activity
associated with rBAT and 4F2-lc6 when expressed either independently or together.
Fig. 2D shows the time course of alanine transport, measured
in the absence of Na+, in cells transfected with pSPORT
vector and in cells coexpressing 4F2hc and 4F2-lc6. The transport
activity was 2-3-fold higher in cells coexpressing the two proteins
than in vector-transfected cells at all time periods tested. When the
transport activity specific for the 4F2hc/4F2-lc6 complex alone was
considered, the transport was linear (r = 0.98) at
least up to 20 min.
Table I describes the specificity of the
transport system mediated by the 4F2hc/4F2-lc6 complex, as evidenced
from direct measurements of the transport of radiolabeled amino acids
and comparison of the transport activities between control cells
transfected with pSPORT vector alone and cells coexpressing 4F2hc and
4F2-lc6. The 4F2hc/4F2-lc6-mediated transport was demonstrable for the neutral amino acids alanine, glutamine, cysteine, cystine, leucine, histidine, and phenylalanine and for the cationic amino acid arginine. The transport of the anionic amino acid glutamate and the transport of
the system A-specific substrate MeAIB were not different between the
control cells and the cells expressing the 4F2hc/4F2-lc6 complex. These
results show that the 4F2hc/4F2-lc6 complex mediates
Na+-independent transport of most of the neutral amino
acids as well as the cationic amino acids.
Table II describes the substrate
specificity of the 4F2hc/4F2-lc6 complex as evidenced from competition
studies. Na+-independent transport of radiolabeled alanine
was measured in control cells transfected with vector alone and in
cells coexpressing 4F2hc and 4F2-lc6, and the ability of various
unlabeled amino acids to inhibit the transport of radiolabeled alanine
was assessed. The 4F2hc/4F2-lc6 complex-specific transport of
[3H]alanine was almost completely inhibited by neutral
amino acids (leucine, tryptophan, phenylalanine, methionine, alanine,
serine, cysteine, threonine, glutamine, asparagine, and glycine) as
well as by cationic amino acids (lysine and arginine). The inhibition was also almost complete with cystine and
2-aminobicyclo(2,2,1)heptane-2-carboxylic acid (an amino acid
considered to be specific for system L). The imino acid proline, the
system A-specific amino acid MeAIB and the anionic amino acids
aspartate and glutamate showed little or no inhibition. Taken
collectively, these data demonstrate that the 4F2hc/4F2-lc6 complex
interacts with neutral amino acids, cationic amino acids, and cystine
in a Na+-independent manner. This substrate specificity is
similar to that of the amino acid transport system b0,+.
Previous studies have shown that rBAT associates with an hitherto unidentified light chain to form the amino acid transport system b0,+ (2, 11, 12). The present studies provide the first
evidence for the presence of a b0,+-like amino acid
transport activity that is independent of rBAT.
We then studied the potency of the neutral amino acids alanine and
leucine, the cationic amino acid lysine, and cystine to inhibit the
Na+-independent transport of [3H]alanine in
control cells transfected with vector alone and in cells coexpressing
4F2hc and 4F2-lc6. Fig. 3 describes the
results with respect to the endogenous [3H]alanine
transport activity and the [3H]alanine transport activity
that is specific to the heterologously expressed 4F2hc/4F2-lc6 complex.
The latter was determined by subtracting the endogenous activity from
the activity measured in cells transfected with 4F2hc cDNA plus
4F2-lc6 cDNA. The endogenous [3H]alanine transport
activity was inhibited by alanine and leucine but not by lysine (Fig.
3A). Cystine showed a small, but significant, inhibition of
the endogenous activity. In contrast, the 4F2hc/4F2-lc6 complex-specific [3H]alanine transport was completely
inhibitable by alanine, leucine, lysine, and cystine (Fig.
3B). The IC50 values (i.e. the
concentrations of unlabeled amino acids needed to cause 50% inhibition
of [3H]alanine transport) for these four amino acids were
25 ± 2, 9 ± 1, 12 ± 3, and 27 ± 3 µM, respectively. Thus, the transport activity specific
to the 4F2hc/4F2-lc6 complex exhibits high affinity toward neutral
amino acids, cationic amino acids, and cystine. The IC50
values for alanine and leucine to inhibit the endogenous [3H]alanine transport were 28 ± 3 and 10 ± 2 µM, respectively.
Fig. 4 describes the saturation kinetics
of Na+-independent alanine transport in control cells
transfected with vector alone and in cells coexpressing 4F2hc and
4F2-lc6. The transport was saturable over an alanine concentration
range of 5-75 µM in both cases. The Michaelis-Menten
constant (Kt) for the 4F2hc/4F2-lc6 complex-specific transport activity was 41 ± 6 µM.
This value was similar to the IC50 value (25 ± 2 µM) determined from the dose-response relationship for
the inhibition of [3H]alanine transport by unlabeled
alanine.
The tissue distribution of the expression of 4F2-lc6 in the rabbit was
studied by Northern blot analysis (Fig.
5). The 4F2-lc6-specific mRNA (2.0 kilobases in size) was detectable only in the small intestine and the
kidney. The other tissues tested (heart, lung, liver, and skeletal
muscle) were negative. To confirm that the northern hybridization
signal obtained with the kidney mRNA represents the
4F2-lc6-specific message, we performed RT-PCR and analyzed the product.
With a pair of primers specific for the rabbit intestinal 4F2-lc6,
mRNA samples from the rabbit intestine (positive control) and the
rabbit kidney yielded RT-PCR products of expected size (980 bp) (data
not shown). These products were subcloned and analyzed for their
restriction pattern with three different restriction enzymes
(BamHI, EcoRI, and StyI). Both
products exhibited an identical restriction pattern, indicating that
both products were identical. This was confirmed by sequence analysis
of the products. These results show unequivocally that the small
intestine and the kidney express 4F2-lc6 mRNA. Interestingly, the
data from the sensitive RT-PCR technique showed that the 4F2-lc6
mRNA is also expressed in other tissues, although to a much lesser
extent than in the intestine and kidney.
Since the ability of the 4F2hc/4F2-lc6 complex to mediate the transport
of cystine is directly relevant to the genetic disorder cystinuria, we
used the X. laevis oocyte expression system to confirm the
4F2hc/4F2-lc6-mediated cystine transport (Fig.
6A). 4F2hc and 4F2-lc6 were
expressed in the oocytes either independently or together by
microinjection of corresponding cRNAs, and the uptake of cystine in
these oocytes was then studied. Expression of 4F2hc alone increased
cystine uptake to a small extent, but expression of 4F2-lc6 alone did
not. However, when both proteins were co-expressed, cystine uptake
increased severalfold compared with water-injected oocytes or oocytes
expressing the two proteins independently.
We have also used the oocyte expression system to demonstrate that the
human rBAT clone used in the present study is functionally active. As
shown in Fig. 6B, the b0,+-like transport
function of rBAT is evident from the increased uptake of cystine,
leucine, and arginine in rBAT-expressing oocytes compared with uptake
in water-injected oocytes.
This is the first report of the molecular identification of a
transporter that is associated with a b0,+-like amino acid
transport activity independent of rBAT. This transporter, designated
4F2-lc6, was cloned from the rabbit intestine. 4F2-lc6 interacts with
the heavy chain of the cell surface antigen 4F2 to induce a
b0,+-like amino acid transport activity. Thus, 4F2-lc6
represents the first light chain subunit to be identified at the
molecular level that is associated with a b0,+-like amino
acid transport activity. This is also the first report showing the
involvement of the 4F2 heavy chain in a b0,+-like transport
activity. Previous studies have shown that the 4F2 heavy chain is
involved in the amino acid transport activities identified as systems
L1, L2, y+L1, y+L2, and
xc The transport activity mediated by the 4F2hc/4F2-lc6 complex shows high
affinity for neutral amino acids, cationic amino acids, and cystine.
The 4F2-lc6-specific message is expressed predominantly in the
intestine and the kidney in the rabbit. The transport characteristics and the tissue distribution pattern suggest that 4F2-lc6 is
a candidate gene for cystinuria. Available evidence indicates that, in
addition to the rBAT gene, there are other genes hitherto
unidentified that are associated with this disease (12). This evidence
includes the following: (a) mutations in the rBAT
gene are responsible for some but not all cystinuria patients,
(b) the genetic locus of the putative subunit that interacts
with the rBAT gene has not been identified, (c)
the rBAT-specific mRNA is detectable only in the proximal straight
tubule of the nephron while the absorption of cystine and cationic
amino acids occurs in the proximal convoluted tubule as well as in the
proximal straight tubule and the proteins responsible for the
absorption in the proximal convoluted tubule have not been identified,
(d) cystinuria presents as different, phenotypically
distinguishable, genetic variants, and (e) multiple genetic
loci have been definitively identified that are associated with the
disease. We suggest that 4F2-lc6 is a candidate gene for cystinuria.
Based on the present studies, there are at least two distinct
b0,+-like amino acid transport activities. One of them
consists of rBAT and a hitherto unidentified subunit, whereas the other
consists of the 4F2 heavy chain and the newly cloned 4F2-lc6. The
rBAT-associated b0,+-like transport process has been shown
to be an obligatory amino acid exchanger (12). However, preliminary
studies with the 4F2hc/4F2-lc6 complex-associated b0,+-like
transport process in mammalian cells have indicated that the transport
process induced by the complex is not an obligatory amino acid
exchanger. Neither the influx nor the efflux of arginine or glutamine
in 4F2hc/4F2-lc6-expressing cells was influenced by other
4F2hc/4F2-lc6-specific substrates on the
trans-side.2 Thus,
there may be significant functional differences between the
b0,+-like transport activities associated with rBAT and
4F2hc/4F2-lc6 complex. The ability of the 4F2hc/4F2-lc6 heterodimeric
complex to induce a b0,+-like amino acid transport activity
implies that mutations not only in the 4F2-lc6 gene but also
in the 4F2hc gene may be associated with cystinuria. To
date, there have been no reports of mutational analysis of the
4F2hc gene in patients with cystinuria. However, it must be
noted that mutations in the 4F2hc gene are likely to affect
not only the b0,+-like transport activity but also the
transport activities identified as L1, L2, y+L1,
y+L2, and xc We thank Ida O. Walker for expert secretarial assistance.
*
This work was supported in part by National Institutes of
Health Grants HD 33347 and DA 10045 (to V. G.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed. Tel.:
706-721-7652; Fax: 706-721-6608; E-mail: vganapat@mail.mcg.edu.
2
D. P. Rajan, R. Kekuda, W. Huang, H. Wang,
L. D. Devoe, F. H. Leibach, P. D. Prasad, and V. Ganapathy, unpublished data.
The abbreviations used are:
rBAT, related to
b0,+ amino acid transporter;
4F2hc, 4F2 heavy chain;
4F2-lc, 4F2 light chain;
MeAIB, 2-(methylamino)isobutyric acid;
LAT, L-amino
acid transporter;
y+LAT, y+L amino acid
transporter;
bp, base pair(s);
HRPE, human retinal pigment
epithelial.
Cloning and Expression of a b0,+-like Amino Acid
Transporter Functioning as a Heterodimer with 4F2hc Instead of rBAT
A NEW CANDIDATE GENE FOR CYSTINURIA*
,
,
,
,
,
, and
§¶
Biochemistry and Molecular
Biology and § Obstetrics and Gynecology, Medical College
of Georgia, Augusta, Georgia 30912
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
(18-25). The
corresponding light chains that associate with 4F2hc to form these
three transport systems have been cloned and functionally characterized. These light chains are referred to as LAT1 and LAT2
(specific for system L) (18-22), y+LAT1 and
y+LAT2 (specific for system y+L) (23, 24), and
xCT (specific for system xc
) (25).
Defects in the y+LAT1 gene have been
recently shown to be responsible for the genetic disorder lysinuric
protein intolerance (26, 27). None of these genes (4F2hc),
LAT1, LAT2,
y+LAT1,
y+LAT2, or xCT) has been
shown to be associated with cystinuria.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-32P]dCTP by random priming using the Ready-to-go
oligolabeling beads. The screening of the rabbit intestinal cDNA
library (31) was done under low stringency conditions using this probe
as described previously (31, 32). Both sense and antisense strands of
the cDNA were sequenced by primer walking using Taq
DyeDeoxy terminator cycle sequencing in an automated Perkin-Elmer
Applied Biosystems 377 Prism DNA sequencer.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (52K):
[in a new window]
Fig. 1.
Primary structure (A) and
predicted membrane topology (B) of 4F2-lc6.

View larger version (32K):
[in a new window]
Fig. 2.
Characteristics of alanine transport
associated with 4F2-lc6. HRPE cells were transfected with pSPORT
vector, human 4F2hc cDNA, human rBAT cDNA, and rabbit 4F2-lc6
cDNA either independently or together. Transport of 1 µM
[3H]alanine was measured in these cells with a 15-min
incubation in the presence (A) or absence (B and
C) of Na+. D, time course of alanine
transport, measured in the absence of Na+, in control cells
transfected with vector alone (
) and in cells coexpressing 4F2hc and
4F2-lc6 (
). The 4F2hc/4F2-lc6 complex-specific
transport is also shown (
). Data are means ± S.E. from
six to eight determinations made with two to three independent
transfections.
4F2hc/4F2-lc6 complex-mediated transport of amino acids
Substrate specificity of the transport process mediated by the
4F2hc/4F2-lc6 complex

View larger version (18K):
[in a new window]
Fig. 3.
A, inhibition of endogenous
[3H]alanine transport measured in cells transfected with
vector alone. B, inhibition of [3H]alanine
transport mediated by the 4F2hc/4F2-lc6 complex. The 4F2hc/4F2-lc6
complex-specific transport was calculated by subtracting the transport
measured in vector-transfected cells from the transport measured in
cells coexpressing 4F2hc and 4F2-lc6. Transport was measured in the
absence of Na+. Data are means ± S.E. from six
determinations made with two independent transfections.
, lysine;
, cystine;
, leucine;
, alanine.

View larger version (17K):
[in a new window]
Fig. 4.
A, saturation kinetics of alanine
transport, measured in the absence of Na+, in cells
transfected with vector alone (
) and in cells coexpressing 4F2hc and
4F2-lc6 (
). B, saturation kinetics of alanine transport
specific for the 4F2hc/4F2-lc6 complex, given either as alanine
concentration versus alanine transport or as an
Eadie-Hofstee plot (inset).

View larger version (24K):
[in a new window]
Fig. 5.
Northern blot analysis of 4F2-lc6 mRNA
expression in rabbit tissues. The blot was hybridized sequentially
with 32P-labeled 4F2-lc6 cDNA and cyclophilin
cDNA.

View larger version (27K):
[in a new window]
Fig. 6.
A, uptake of cystine (1 µM) in X. laevis oocytes expressing
4F2hc and 4F2-lc6 either independently or together. B,
uptake of cystine, leucine, and arginine in water-injected oocytes and
in rBAT-expressing oocytes. Concentration of amino acids was 1 µM.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
(18-25). To date, the only protein
that has been shown to be involved in a b0,+-like amino
acid transport activity is rBAT (7, 8). This protein shows a
significant homology to the 4F2 heavy chain and is believed to
constitute one of the subunits of the b0,+-like transport
system (2, 11, 12). However, the other putative subunit that associates
with rBAT has not been identified. The 4F2-lc6 reported in this paper
is a subunit of a b0,+-like transport system, but does not
interact with rBAT.
since 4F2hc
is a common subunit of these transport systems. On the other hand,
mutations in the 4F2-lc6 gene are likely to affect only the
b0,+-like transport activity.
![]()
ACKNOWLEDGEMENT
![]()
FOOTNOTES
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Segal, S.,
and Thier, S.
(1995)
in
The Metabolic and Molecular Bases of Inherited Diseases
(Scriver, C. H.
, Beaudet, A.
, Sly, W. S.
, and Valle, D., eds)
, pp. 3581-3601, McGraw-Hill, New York
2.
Palacin, M.,
Chillaron, J.,
and Mora, C.
(1996)
Biochem. Soc. Trans.
24,
856-863[Medline]
[Order article via Infotrieve]
3.
Gitomer, W. L.,
and Pak, C. Y.
(1996)
J. Urol.
156,
1907-1912[CrossRef][Medline]
[Order article via Infotrieve]
4.
Pierides, A. M.
(1997)
Contrib. Nephrol.
122,
167-172[Medline]
[Order article via Infotrieve]
5.
Bruno, M.,
and Marangella, M.
(1997)
Contrib. Nephrol.
122,
173-177[Medline]
[Order article via Infotrieve]
6.
Tate, S. S.,
Yan, N.,
and Udenfriend, S.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
1-5 7.
Wells, R. G.,
and Hediger, M. A.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
5596-5600 8.
Bertran, J.,
Werner, A.,
Moore, M. L.,
Strange, G.,
Markovich, D.,
Biber, J.,
Testar, X.,
Zorzano, A.,
Palacin, M.,
and Murer, H.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
5601-5605 9.
Pickel, V. M.,
Nirenberg, M. J.,
Chan, J.,
Mosckovitz, R.,
Udenfriend, S.,
and Tate, S. S.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
7779-7783 10.
Van Winkle, L. J.,
Campione, A. L.,
and Gorman, J. M.
(1988)
J. Biol. Chem.
263,
3150-3163 11.
Palacin, M.,
Mora, C.,
Chillaron, J.,
Calonge, M. J.,
Estevez, R.,
Torrents, D.,
Testar, X.,
Zorzano, A.,
Nunes, V.,
Purroy, J.,
Estevill, X.,
Gasparini, P.,
Besceglia, L.,
and Zelante, L.
(1996)
Amino Acids
11,
225-246
12.
Palacin, M.,
Estevez, R.,
Bertran, J.,
and Zorzano, A.
(1998)
Physiol. Rev.
78,
969-1054 13.
Rosenberg, L. E.,
Downing, S.,
Durant, J. L.,
and Segal, S.
(1966)
J. Clin. Invest.
45,
365-371
14.
Bertran, J.,
Magagnin, S.,
Werner, A.,
Markovich, D.,
Biber, J.,
Testar, X.,
Zorzano, A.,
Kuhn, L. C.,
Palacin, M.,
and Murer, H.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
5606-5610 15.
Wells, R. G.,
Lee, W.,
Kanai, Y.,
Leiden, J. M.,
and Hediger, M. A.
(1992)
J. Biol. Chem.
267,
15285-15288 16.
Fei, Y. J.,
Prasad, P. D.,
Leibach, F. H.,
and Ganapathy, V.
(1995)
Biochemistry
34,
8744-8751[CrossRef][Medline]
[Order article via Infotrieve]
17.
Deves, R.,
and Boyd, C. A. R.
(1998)
Physiol. Rev.
78,
487-545 18.
Kanai, Y.,
Segawa, H.,
Miyamoto, K.,
Uchino, H.,
Takeda, E.,
and Endou, H.
(1998)
J. Biol. Chem.
273,
23629-23632 19.
Mastroberardino, L.,
Spindler, B.,
Pfeiffer, R.,
Skelly, P. J.,
Loffing, J.,
Shoemaker, C. B.,
and Verrey, F.
(1998)
Nature
395,
288-291[CrossRef][Medline]
[Order article via Infotrieve]
20.
Prasad, P. D.,
Wang, H.,
Huang, W.,
Kekuda, R.,
Rajan, D. P.,
Leibach, F. H.,
and Ganapathy, V.
(1999)
Biochem. Biophys. Res. Commun.
255,
283-288[CrossRef][Medline]
[Order article via Infotrieve]
21.
Pineda, M.,
Fernandez, E.,
Torrents, D.,
Estevez, R.,
Lopez, C.,
Camps, M.,
Lloberas, J.,
Zorzano, A.,
and Palacin, M.
(1999)
J. Biol. Chem.
274,
19738-19744 22.
Segawa, H.,
Fukasawa, Y.,
Miyamoto, K. I.,
Takeda, E.,
Endou, H.,
and Kanai, Y.
(1999)
J. Biol. Chem.
274,
19745-19751 23.
Torrents, D.,
Estevez, R.,
Pineda, M.,
Fernandez, E.,
Lloberas, J.,
Shi, Y. B.,
Zorzano, A.,
and Palacin, M.
(1998)
J. Biol. Chem.
273,
32437-32445 24.
Pfeiffer, R.,
Rossier, G.,
Spindler, B.,
Meier, C.,
Kuhn, L.,
and Verrey, F.
(1999)
EMBO J.
18,
49-57[CrossRef][Medline]
[Order article via Infotrieve]
25.
Sato, H.,
Tamba, M.,
Ishii, T.,
and Bannai, S.
(1999)
J. Biol. Chem.
274,
11455-11458 26.
Torrents, D.,
Mykkanen, J.,
Pineda, M.,
Feliubadalo, L.,
Estevez, R.,
de Cid, R.,
Sanjurjo, P.,
Zorzano, A.,
Nunes, V.,
Huoponen, K.,
Reinikainen, A.,
Simell, O.,
Savontaus, M. L.,
Aula, P.,
and Palacin, M.
(1999)
Nat. Genet.
21,
293-296[CrossRef][Medline]
[Order article via Infotrieve]
27.
Borsani, G.,
Bassi, M. T.,
Sperandeo, M. P.,
de Grandi, A.,
Buoninconti, A.,
Riboni, M.,
Manzoni, M.,
Incerti, B.,
Pepe, A.,
Andria, G.,
Ballabio, A.,
and Sebastio, G.
(1999)
Nat. Genet.
21,
297-301[CrossRef][Medline]
[Order article via Infotrieve]
28.
Ramamoorthy, S.,
Del Monte, M. A.,
Leibach, F. H.,
and Ganapathy, V.
(1994)
Curr. Eye Res.
13,
523-529[Medline]
[Order article via Infotrieve]
29.
Huang, W.,
Prasad, P. D.,
Kekuda, R.,
Leibach, F. H.,
and Ganapathy, V.
(1997)
Invest. Ophthalmol. Vis. Sci.
38,
1578-1587 30.
Kekuda, R.,
Prasad, P. D.,
Wu, X.,
Wang, H.,
Fei, Y. J.,
Leibach, F. H.,
and Ganapathy, V.
(1998)
J. Biol. Chem.
273,
15971-15979 31.
Kekuda, R.,
Torres-Zamorano, V.,
Fei, Y. J.,
Prasad, P. D.,
Li, H. W.,
Mader, L. D.,
Leibach, F. H.,
and Ganapathy, V.
(1997)
Am. J. Physiol.
272,
G1463-G1472 32.
Prasad, P. D.,
Wang, H.,
Kekuda, R.,
Fujita, T.,
Fei, Y. J.,
Devoe, L. D.,
Leibach, F. H.,
and Ganapathy, V.
(1998)
J. Biol. Chem.
273,
7501-7506
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
T. Z. Su, M. R. Feng, and M. L. Weber Mediation of Highly Concentrative Uptake of Pregabalin by L-Type Amino Acid Transport in Chinese Hamster Ovary and Caco-2 Cells J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1406 - 1415. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. I. Closs, A. Simon, N. Vekony, and A. Rotmann Plasma Membrane Transporters for Arginine J. Nutr., October 1, 2004; 134(10): 2752S - 2759S. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. C. Bridges, H. Hu, S. Miyauchi, U. N. Siddaramappa, M. E. Ganapathy, L. Ignatowicz, D. M. Maddox, S. B. Smith, and V. Ganapathy Induction of Cystine-Glutamate Transporter xc- by Human Immunodeficiency Virus Type 1 Transactivator Protein Tat in Retinal Pigment Epithelium Invest. Ophthalmol. Vis. Sci., September 1, 2004; 45(9): 2906 - 2914. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Quan, K. Athirakul, W. C. Wetsel, G. E. Torres, R. Stevens, Y. T. Chen, T. M. Coffman, and M. G. Caron Hypertension and Impaired Glycine Handling in Mice Lacking the Orphan Transporter XT2 Mol. Cell. Biol., May 15, 2004; 24(10): 4166 - 4173. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. C. Bridges, C. Bauch, F. Verrey, and R. K. Zalups Mercuric Conjugates of Cysteine Are Transported by the Amino Acid Transporter System b0,+: Implications of Molecular Mimicry J. Am. Soc. Nephrol., March 1, 2004; 15(3): 663 - 673. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Veljkovic, S. Stasiuk, P. J. Skelly, C. B. Shoemaker, and F. Verrey Functional Characterization of Caenorhabditis elegans Heteromeric Amino Acid Transporters J. Biol. Chem., February 27, 2004; 279(9): 7655 - 7662. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. E. Mann, D. L. Yudilevich, and L. Sobrevia Regulation of Amino Acid and Glucose Transporters in Endothelial and Smooth Muscle Cells Physiol Rev, January 1, 2003; 83(1): 183 - 252. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Inoue, L. Zhuang, D. M. Maddox, S. B. Smith, and V. Ganapathy Structure, Function, and Expression Pattern of a Novel Sodium-coupled Citrate Transporter (NaCT) Cloned from Mammalian Brain J. Biol. Chem., October 11, 2002; 277(42): 39469 - 39476. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Fernandez, M. Carrascal, F. Rousaud, J. Abian, A. Zorzano, M. Palacin, and J. Chillaron rBAT-b0,+AT heterodimer is the main apical reabsorption system for cystine in the kidney Am J Physiol Renal Physiol, September 1, 2002; 283(3): F540 - F548. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Bauch and F. Verrey Apical heterodimeric cystine and cationic amino acid transporter expressed in MDCK cells Am J Physiol Renal Physiol, July 1, 2002; 283(1): F181 - F189. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Chillaron, R. Roca, A. Valencia, A. Zorzano, and M. Palacin Heteromeric amino acid transporters: biochemistry, genetics, and physiology Am J Physiol Renal Physiol, December 1, 2001; 281(6): F995 - F1018. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Wagner, F. Lang, and S. Broer Function and structure of heterodimeric amino acid transporters Am J Physiol Cell Physiol, October 1, 2001; 281(4): C1077 - C1093. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. P. Bode Recent Molecular Advances in Mammalian Glutamine Transport J. Nutr., September 1, 2001; 131(9): 2475S - 2485. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. C. Bridges, R. Kekuda, H. Wang, P. D. Prasad, P. Mehta, W. Huang, S. B. Smith, and V. Ganapathy Structure, Function, and Regulation of Human Cystine/Glutamate Transporter in Retinal Pigment Epithelial Cells Invest. Ophthalmol. Vis. Sci., January 1, 2001; 42(1): 47 - 54. [Abstract] [Full Text] |
||||
![]() |
D. P. Rajan, W. Huang, R. Kekuda, R. L. George, J. Wang, S. J. Conway, L. D. Devoe, F. H. Leibach, P. D. Prasad, and V. Ganapathy Differential Influence of the 4F2 Heavy Chain and the Protein Related to b0,+ Amino Acid Transport on Substrate Affinity of the Heteromeric b0,+ Amino Acid Transporter J. Biol. Chem., May 5, 2000; 275(19): 14331 - 14335. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sugawara, T. Nakanishi, Y.-J. Fei, W. Huang, M. E. Ganapathy, F. H. Leibach, and V. Ganapathy Cloning of an Amino Acid Transporter with Functional Characteristics and Tissue Expression Pattern Identical to That of System A J. Biol. Chem., May 26, 2000; 275(22): 16473 - 16477. [Abstract] [Full Text] [PDF] |
||||